genomic profiling

$Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program$

Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program

By MedXY 03/06/2026

This review synthesizes findings from the Australian MoST program, demonstrating that genomically matched therapies significantly improve overall survival in advanced solid tumors only when supported by high-level prospective clinical trial evidence.

Hematology-Oncology news

Beyond Standard Staging: A Novel Genetics-Based Model Refines Prognosis for AML Patients Treated with Venetoclax and Hypomethylating Agents

By MedXY 02/14/2026

A newly developed prognostic model integrates mutational and cytogenetic data to accurately predict survival in AML patients receiving HMA/VEN therapy, offering superior risk stratification into low-, intermediate-, and high-risk categories with distinct survival durations.

General Surgery news Oncology

Beyond Nodal Status: A New Risk Score Predicts Recurrence in Lymph Node-Negative Pancreatic Neuroendocrine Tumors

By MedXY 12/22/2025

A multi-center study in JAMA Surgery introduces a validated 13-point risk score to identify recurrence risk in LN-negative PanNET patients, revealing that tumor size, grade, and lymphovascular invasion are critical prognostic drivers even when nodes are clear.

news Oncology

Genomically Matched Therapy Improves Response and PFS Across Advanced Solid Tumors: Phase 2 ROME Trial

By MedXY 11/12/2025

The randomized phase 2 ROME trial showed that genomically matched, MTB-guided therapy increased overall response rate and progression-free survival versus standard care in heavily pretreated advanced solid tumors, supporting a tumor-agnostic precision oncology strategy despite unchanged overall survival due to crossover.

Hematology-Oncology news

Decoding Progression Risk in IgM-MGUS and Asymptomatic Waldenström Macroglobulinemia Through Genomic Profiling

By MedXY 10/14/2025

This article explores how genomic features differentiate stable from progressive asymptomatic Waldenström macroglobulinemia and IgM-MGUS, highlighting mutation burdens, specific gene alterations, and aneuploidy as prognostic markers for disease progression.